Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy

Davide Pareyson, Pietro Fratta, Pierre François Pradat, Gianni Sorarù, Josef Finsterer, John Vissing, Manu E. Jokela, Bjarne Udd, Albert C. Ludolph, Anna Sagnelli, Patrick Weydt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pathomechanisms of spinal and bulbar muscular atrophy (SBMA) have been extensively investigated and are partially understood, but no effective treatment is currently available for this disabling disorder. Its rarity, the slow disease progression, and lack of sensitive-to-change outcome measures render design and conduction of clinical trials a challenging task. Therefore, it is fundamental to strengthen the network of clinical centers interested in SBMA for clinical trial readiness. We propose to create and maintain an International SBMA Registry where as many well-characterized patients as possible can be included, with the following aims: facilitate planning of clinical trials and recruitment of patients, define natural history of the disease, characterize epidemiology, develop standards of care, and inform the community of patients about research progresses and ongoing trials. We also aim at developing harmonized and coordinated biorepositories. The experience obtained during the last years in the field of other neuromuscular disorders and of Huntington disease offers valuable precedents.

Original languageEnglish
Pages (from-to)394-400
Number of pages7
JournalJournal of Molecular Neuroscience
Volume58
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Atrophic Muscular Disorders
Registries
Clinical Trials
Huntington Disease
Standard of Care
Patient Selection
Disease Progression
Epidemiology
Outcome Assessment (Health Care)
Research
Therapeutics

Keywords

  • Biorepository
  • Clinical trials
  • Kennedy disease
  • Registry
  • Spinal and bulbar muscular atrophy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. / Pareyson, Davide; Fratta, Pietro; Pradat, Pierre François; Sorarù, Gianni; Finsterer, Josef; Vissing, John; Jokela, Manu E.; Udd, Bjarne; Ludolph, Albert C.; Sagnelli, Anna; Weydt, Patrick.

In: Journal of Molecular Neuroscience, Vol. 58, No. 3, 01.03.2016, p. 394-400.

Research output: Contribution to journalArticle

Pareyson, D, Fratta, P, Pradat, PF, Sorarù, G, Finsterer, J, Vissing, J, Jokela, ME, Udd, B, Ludolph, AC, Sagnelli, A & Weydt, P 2016, 'Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy', Journal of Molecular Neuroscience, vol. 58, no. 3, pp. 394-400. https://doi.org/10.1007/s12031-015-0704-5
Pareyson, Davide ; Fratta, Pietro ; Pradat, Pierre François ; Sorarù, Gianni ; Finsterer, Josef ; Vissing, John ; Jokela, Manu E. ; Udd, Bjarne ; Ludolph, Albert C. ; Sagnelli, Anna ; Weydt, Patrick. / Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy. In: Journal of Molecular Neuroscience. 2016 ; Vol. 58, No. 3. pp. 394-400.
@article{a339458ba9074d2cb9e48d89925d549d,
title = "Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy",
abstract = "Pathomechanisms of spinal and bulbar muscular atrophy (SBMA) have been extensively investigated and are partially understood, but no effective treatment is currently available for this disabling disorder. Its rarity, the slow disease progression, and lack of sensitive-to-change outcome measures render design and conduction of clinical trials a challenging task. Therefore, it is fundamental to strengthen the network of clinical centers interested in SBMA for clinical trial readiness. We propose to create and maintain an International SBMA Registry where as many well-characterized patients as possible can be included, with the following aims: facilitate planning of clinical trials and recruitment of patients, define natural history of the disease, characterize epidemiology, develop standards of care, and inform the community of patients about research progresses and ongoing trials. We also aim at developing harmonized and coordinated biorepositories. The experience obtained during the last years in the field of other neuromuscular disorders and of Huntington disease offers valuable precedents.",
keywords = "Biorepository, Clinical trials, Kennedy disease, Registry, Spinal and bulbar muscular atrophy",
author = "Davide Pareyson and Pietro Fratta and Pradat, {Pierre Fran{\cc}ois} and Gianni Sorar{\`u} and Josef Finsterer and John Vissing and Jokela, {Manu E.} and Bjarne Udd and Ludolph, {Albert C.} and Anna Sagnelli and Patrick Weydt",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s12031-015-0704-5",
language = "English",
volume = "58",
pages = "394--400",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy

AU - Pareyson, Davide

AU - Fratta, Pietro

AU - Pradat, Pierre François

AU - Sorarù, Gianni

AU - Finsterer, Josef

AU - Vissing, John

AU - Jokela, Manu E.

AU - Udd, Bjarne

AU - Ludolph, Albert C.

AU - Sagnelli, Anna

AU - Weydt, Patrick

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Pathomechanisms of spinal and bulbar muscular atrophy (SBMA) have been extensively investigated and are partially understood, but no effective treatment is currently available for this disabling disorder. Its rarity, the slow disease progression, and lack of sensitive-to-change outcome measures render design and conduction of clinical trials a challenging task. Therefore, it is fundamental to strengthen the network of clinical centers interested in SBMA for clinical trial readiness. We propose to create and maintain an International SBMA Registry where as many well-characterized patients as possible can be included, with the following aims: facilitate planning of clinical trials and recruitment of patients, define natural history of the disease, characterize epidemiology, develop standards of care, and inform the community of patients about research progresses and ongoing trials. We also aim at developing harmonized and coordinated biorepositories. The experience obtained during the last years in the field of other neuromuscular disorders and of Huntington disease offers valuable precedents.

AB - Pathomechanisms of spinal and bulbar muscular atrophy (SBMA) have been extensively investigated and are partially understood, but no effective treatment is currently available for this disabling disorder. Its rarity, the slow disease progression, and lack of sensitive-to-change outcome measures render design and conduction of clinical trials a challenging task. Therefore, it is fundamental to strengthen the network of clinical centers interested in SBMA for clinical trial readiness. We propose to create and maintain an International SBMA Registry where as many well-characterized patients as possible can be included, with the following aims: facilitate planning of clinical trials and recruitment of patients, define natural history of the disease, characterize epidemiology, develop standards of care, and inform the community of patients about research progresses and ongoing trials. We also aim at developing harmonized and coordinated biorepositories. The experience obtained during the last years in the field of other neuromuscular disorders and of Huntington disease offers valuable precedents.

KW - Biorepository

KW - Clinical trials

KW - Kennedy disease

KW - Registry

KW - Spinal and bulbar muscular atrophy

UR - http://www.scopus.com/inward/record.url?scp=84961130421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961130421&partnerID=8YFLogxK

U2 - 10.1007/s12031-015-0704-5

DO - 10.1007/s12031-015-0704-5

M3 - Article

VL - 58

SP - 394

EP - 400

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -